Upcoming Issue Highlights
Home Subscribe Advertise Sourcebook Free Product Info Home

Rod Shelley, Business Development Manager, Marinova

K2VITAL®
 
Albion Minerals®
Rod Shelley Rod Shelley

Marinova Pty Ltd
249 Kennedy Dr.
Cambridge, Tasmania 7170 Australia
Phone: +61 3 6248 5800
Website: www.marinova.com.au

Marinova Pty Ltd is an Australian biotechnology company dedicated to the development and production of high purity seaweed extracts. Marinova specializes in the research, development and manufacture of fucoidan compounds—highly bioactive polysaccharides derived from select species of brown seaweed.

Rod Shelley is an experienced business leader with strong commercial acumen. He has extensive experience in international markets and is known for his strategic approach to identifying and securing new market opportunities.

NIE: In 2023, Marinova celebrates its 20th anniversary. What are some of the company’s achievements since its creation?

Shelley: The 2023 milestone marks two decades of dedication to the research, development and manufacture of high purity fucoidan compounds. Marinova’s reputation as the global leader in fucoidan science is built on the unrivalled quality and efficacy of its bioactive fucoidan ingredients. More than 2,500 independent, peer-reviewed research papers have now been published on the bioactive properties of fucoidans. This extensive body of evidence includes comprehensive in vitro investigations, animal studies and human clinical trials. The vast majority of this research has been conducted in the last 20 years, with Marinova leading the way.

Manufacturers of fucoidan have traditionally [utilized] solvents to precipitate the fucoidan polymer from crude seaweed extracts. This methodology may lead to contaminants being present in the final extract. Fucoidans manufactured in this way can suffer from many shortfalls; their quality can be inconsistent, their chemical integrity may be compromised and—most importantly—their bioactivity may be affected.

Marinova’s exclusive extraction technology overcomes these problems. The company’s proprietary Maritech extraction process employs “green chemistry” principles to produce fucoidan extracts that remain unadulterated in chemical structure and free from solvent residues. The mild, aqueous process also ensures the resulting extracts comply with the most rigorous quality standards and regulatory requirements. It is by virtue of this proprietary process that the company’s unique portfolio of Maritech fucoidans are the world’s only high purity, certified organic fucoidans with global regulatory acceptance.

NIE: The company is currently undergoing a major expansion at its fucoidan extraction facility in Tasmania, Australia. Talk about the expansion and what Marinova hopes to accomplish with it.

Shelley: Natural, certified organic, efficacious and sustainably sourced ingredients that are supported by an extensive dossier of scientific evidence are in high global demand. In response to the rising global demand for high purity fucoidans, Marinova is currently undertaking a $5 million expansion of its state-of-the-art production facility in Australia. The significant capital expansion will allow Marinova to triple its fucoidan production capacity. The project is well underway and set to be completed by mid-2024.

NIE: Marinova is part of Australia’s Marine Bioproducts Cooperative Research Centre (MB-CRC). What is the MB-CRC, and how will Marinova be involved?

Shelley: Australia has made a bold move to supercharge its dynamic marine bioproducts industry through a $270 million, decade-long R&D program. The Marine Bioproducts Cooperative Research Centre (MB-CRC) is a consortium of more than 70 innovative Australian partners from academia and industry focused on developing the country’s marine bio-industries. Current estimates suggest Australia’s high-quality marine bioproducts are on track to reach $1 billion in turnover by 2030.

Marinova’s involvement in the MB-CRC will fast-track a number of very significant research projects. The company expects enormous commercial opportunities to emerge from its expanding research program, particularly in the areas of immune support, gut & digestive health and healthy aging. Marinova’s commitment to science remains unwavering and the opportunities here in Australia for superior algal-derived products are huge.

NIE: What steps does the company take to ensure quality and sustainability?

Shelley: Marinova is a biotechnology leader committed to excellence. When you choose Marinova, you are buying into a commitment to provide the highest quality and most effective fucoidan extracts on the market. Marinova adheres to meticulous quality assurance protocols and safety standards, implementing rigorous testing procedures and traceability systems throughout its operations. Marinova is an ISO9001 and HACCP certified company, producing high purity fucoidan extracts under GMP (good manufacturing practice).

The sustainability credentials of Maritech organic fucoidans are closely aligned with the Sustainable Development Goals identified by the United Nations. These credentials span the entire length of the supply chain and include the hand harvesting of wild seaweeds, the proprietary green chemistry extraction technology, the productive reuse of by-product, and the utilisation of renewable energy.

NIE: What should brand owners and formulators know about Marinova?

Shelley: High purity, certified organic fucoidans offer versatility, efficacy and stability across a wide range of nutritional, cosmetic and animal health applications. They are ideal for formulators seeking innovative ingredients with a clear point of differentiation.

Fucoidan is typically supplied as a dry powder and can be utilized as a stand-alone bioactive or easily incorporated with other ingredients. High purity fucoidan is ideal for inclusion in:

• Capsules
• Medical devices
• Functional beverages
• Pressed tablets
• Bulk supplement powders- gels, creams and serums.

Albion Minerals®
 
CapsCanada